AllianceBernstein’s Cascadian Therapeutics, Inc. CASC Stock Holding History

AllianceBernstein’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-12,183	Closed	-$93K	–	3024
2016 Q1	$93K	Hold	12,183	–	–	﹤0.01%	2829
2015 Q4	$162K	Hold	12,183	–	–	﹤0.01%	2791
2015 Q3	$200K	Hold	12,183	–	–	﹤0.01%	2779
2015 Q2	$273K	Buy	12,183 +11,650	+2,186%	+$184K	﹤0.01%	2780
2015 Q1	$5K	Hold	533	–	–	﹤0.01%	3428
2014 Q4	$6K	Hold	533	–	–	﹤0.01%	3366
2014 Q3	$6K	Sell	533 -534	-50%	-$8.16K	﹤0.01%	3345
2014 Q2	$21K	Buy	1,067 +928	+668%	+$16.4K	﹤0.01%	3228
2014 Q1	$2K	Hold	139	–	–	﹤0.01%	3490
2013 Q4	$1K	Hold	139	–	–	﹤0.01%	3402
2013 Q3	$2K	Sell	139 -794	-85%	-$8.36K	﹤0.01%	3305
2013 Q2	$9K	Buy	+933	New	+$12K	﹤0.01%	3157

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein's CASC Position: Q2 2016 in Review

AllianceBernstein sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 12,183 shares — an estimated $93K sold.

AllianceBernstein first reported a position in CASC in Q2 2013 and held it in 12 quarters. The position peaked at $273K in Q2 2015. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

AllianceBernstein reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
AllianceBernstein sold 12,183 Cascadian Therapeutics, Inc. shares in Q2 2016, an estimated $93K.
AllianceBernstein first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
AllianceBernstein's Cascadian Therapeutics, Inc. position peaked at $273K in Q2 2015.
75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on AllianceBernstein's 13F filing for Q2 2016, filed 11 Aug 2016.